Letrozole OR Anastrozole

Phase 3Small molecule

Novartis

Letrozole OR Anastrozole is one of 26 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerRecruiting

Breast CancerPhase 3

Recruiting

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Letrozole OR Anastrozole

Novartis

Phase 3

4 2

Adenocard

Astellas

Preclinical

2 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 6

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 7

Tianeptine

Pfizer

Preclinical

1 8

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 9

Bisphosphonate

Amgen

Preclinical

2 10

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Breast Cancer

NCT04886531

Clinical

Trials by Indication[1]

Breast Cancer4 trials

A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer

Not yet recruiting·TThe Affiliated Hospital of Qingdao University··NCT06341283·200 enrolled

A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03966898·426 enrolled

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT03839823·222 enrolled

Show 1 more trial

An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Cancers Hoosier Cancer Research Network BRE17-141

Recruiting·RRuth O'Regan·Phase 2·NCT04886531·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Letrozole OR Anastrozole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Letrozole OR Anastrozole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Letrozole OR Anastrozole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Letrozole OR Anastrozole

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Breast Cancer4 trials

References

Drug Info

Quick Facts

Related News